Showing results (101-110 of 144) with videos related to
Sort By:
Pageof 15
Plos One|July 16, 2015
The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic FactorsAgnieszka Czarniecka, Monika Kowal, Dagmara Rusinek, et al.European Journal of Nuclear Medicine and Molecular Imaging|January 27, 2016
Gene signature of the post-Chernobyl papillary thyroid cancerDaria Handkiewicz-Junak, Michal Swierniak, Dagmara Rusinek, et al.Endokrynologia Polska|March 6, 2010
Germinal mutations of RET, SDHB, SDHD, and VHL genes in patients with apparently sporadic pheochromocytomas and paragangliomasAleksandra Krawczyk, Kornelia Hasse-Lazar, Agnieszka Pawlaczek, et al.Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.BMC Medical Genomics|October 9, 2013
Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissuesAleksandra Pfeifer, Bartosz Wojtas, Malgorzata Oczko-Wojciechowska, et al.Thyroid : Official Journal of the American Thyroid Association|April 11, 2022
A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid CancerJaume Capdevila, Arkadiy Klochikhin, Sophie Leboulleux, et al.Proceedings of the National Academy of Sciences of the United States of America|May 26, 2010
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progressionCarmelo Nucera, Alessandro Porrello, Zeus Andrea Antonello, et al.International Journal of Molecular Sciences|September 12, 2018
Coexistence ofDagmara Rusinek, Aleksandra Pfeifer, Jolanta Krajewska, et al.Cancer|May 22, 2014
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessmentsLaura D Locati, Lisa Licitra, Laura Agate, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2009
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancerMartin J Schlumberger, Rossella Elisei, Lars Bastholt, et al.Pageof 15